Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner

References

• Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. 2016. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell. 27:2757–2770.
   PubMed Web of Science ®Google Scholar
• Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. 2009. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 15:4423–4430.
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J. 2011. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One. 6:e24426.
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 118:64–78.
   PubMed Web of Science ®Google Scholar
• Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullrich RK. 2002. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene. 21:4032–4041.
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. 2006. Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319.
   PubMed Web of Science ®Google Scholar
• Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. 2011. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One. 6:e17649.
   PubMed Web of Science ®Google Scholar
• Hamaoka Y, Negishi M, Katoh H. 2016. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cell Signal. 28:937–945.
   PubMed Web of Science ®Google Scholar
• Kawai H, Kobayashi M, Hiramoto-Yamaki N, Harada K, Negishi M, Katoh H. 2013. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio. 3:78–82.
   PubMed Web of Science ®Google Scholar
• Li X, Wang L, Gu JW, Li B, Liu WP, Wang YG, Zhang X, Zhen HN, Fei Z. 2010. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumor Biol. 31:477–488.
   PubMed Web of Science ®Google Scholar
• Lisabeth EM, Falivelli G, Pasquale EB. 2016. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 5:a009159.
   Google Scholar
• Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. 2015a. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 5:274–287.
   PubMed Web of Science ®Google Scholar
• Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, Murphy AJ, Valenzuela DM, Yancopoulos G, Hambardzumyan D, et al. 2015b. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 34:558–567.
   PubMed Web of Science ®Google Scholar
• Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, et al. 2009. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 16:9–20.
   PubMed Web of Science ®Google Scholar
• Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. 2001. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol. 3:527–530.
   PubMed Web of Science ®Google Scholar
• Mosch B, Pietzsch D, Pietzsch J. 2012. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr. 6:113–125.
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, et al. 2015. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 5:264–273.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 10:165–180.
   PubMed Web of Science ®Google Scholar
• Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, et al. 2007. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 401:29–38.
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G, Lin PS. 2003. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene. 22:5855–5865.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yamada N, Tanaka T, Hori T, Yokoyama S, Hayakawa Y, Yano S, Fukuoka J, Koizumi K, Saiki I, Sakurai H. 2015. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat Comms. 6:7679.
   PubMed Web of Science ®Google Scholar